Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Global Pharma and Biotech Clinical Stage Partnering Terms and Agreements Report 2019: Comprehensive Listing of Over 1,700 Clinical Stage Partnering Deals Announced Since 2014

      Research and Markets Logo

      News provided by

      Research and Markets

      Sep 05, 2019, 10:00 ET

      Share this article

      Share this article


      DUBLIN, Sept. 5, 2019 /PRNewswire/ -- The "Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2019" report has been added to ResearchAndMarkets.com's offering.

      The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014- 2019 report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector.

      Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

      This report contains a comprehensive listing of over 1,700 clinical stage partnering deals announced since 2014 including financial terms where available including numerous links to online deal records of actual clinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

      The initial chapters of this report provide an orientation of clinical stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner clinical stage compounds/products.

      Chapter 3 provides an overview of clinical stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in clinical stage deals.

      Chapter 5 provides a review of clinical stage deal making since 2014. Deals activity is reviewed by year, stage of development at signing, therapeutic area, technology type, as well as most active dealmakers.

      Chapter 6 provides a detailed analysis of clinical stage payment terms including headline, upfront, milestone and royalty rates for phase I, phase II and phase III deals.

      Chapter 7 provides a review of the leading clinical stage deal by headline value. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

      Chapter 8 provides a comprehensive listing of the top 25 most active clinical stage dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

      Chapter 9 provides a comprehensive and detailed review of clinical stage partnering deals signed and announced since 2014, where a contract document is available in the public domain.

      Chapter 10 provides a comprehensive directory of clinical stage partnering deals since 2014 organized by stage of development - phase I, phase II and phase III.

      The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

      The report also includes numerous tables and figures that illustrate the trends and activities in clinical stage partnering and deal making since 2014.

      In addition, a comprehensive appendix of all clinical stage deals since 2014 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

      In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of clinical stage products and compounds.

      Report Scope

      Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014- 2019 includes:

      • Trends in clinical stage dealmaking in the biopharma industry since 2014
      • Analysis of clinical stage deal structure
      • Access to headline, upfront, milestone and royalty data
      • Case studies of real-life clinical stage deals
      • Access to over 1,700 clinical stage deals
      • The leading clinical stage deals by value since 2014
      • Most active clinical stage dealmakers since 2014
      • The leading clinical stage partnering resources

      Available contracts are listed by:

      • Company A-Z
      • Headline value
      • Stage of development at signing
      • Deal type
      • Specific therapy target

      Analyzing actual contract agreements allows assessment of the following:

      • What are the precise rights granted or optioned?
      • What is actually granted by the agreement to the partner company?
      • What exclusivity is granted?
      • What is the payment structure for the deal?
      • How are sales and payments audited?
      • What is the deal term?
      • How are the key terms of the agreement defined?
      • How are IPRs handled and owned?
      • Who is responsible for commercialization?
      • Who is responsible for development, supply, and manufacture?
      • How is confidentiality and publication managed?
      • How are disputes to be resolved?
      • Under what conditions can the deal be terminated?
      • What happens when there is a change of ownership?
      • What sublicensing and subcontracting provisions have been agreed?
      • Which boilerplate clauses does the company insist upon?
      • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
      • Which jurisdiction does the company insist upon for agreement law?

      Key Topics Covered:

      Executive Summary

      Chapter 1 - Introduction

      Chapter 2 - Why do companies partner clinical stage compounds?
      2.1. Introduction
      2.2. The role of clinical stage partnering
      2.2.1. In-licensing at clinical stage
      2.2.2. Out-licensing at clinical stage
      2.3. Difference between phase I, II and III stage deals
      2.4. Reasons for entering into clinical stage partnering deals
      2.4.1. Licensors reasons for entering clinical stage deals
      2.4.2. Licensees reasons for entering clinical stage deals
      2.5. The future of clinical stage partnering deals

      Chapter 3 - Clinical stage deal strategies and structure
      3.1. Introduction
      3.2. At what stage do companies partner?
      3.2.1. Partnering early in pharmaceutical/biotech
      3.2.1.1. Discovery and preclinical stage partnering case studies
      3.2.1.1.a. Case study: LEO Pharma - 4SC
      3.2.1.1.b. Case study: Heptares Therapeutics - Cubist
      3.2.1.1.c. Case study: Incyte - Agenus Bio
      3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec
      3.2.2. Partnering later in pharmaceutical/biotech
      3.2.2.1. Clinical stage partnering case studies
      3.2.2.1.a. Case study: Servier - GeNeuro
      3.2.2.1.b. Case study: Teva - Xenon Pharmaceuticals
      3.2.2.1.c. Case study: AstraZeneca - Ardelyx
      3.2.2.1.d. Case study: Baxter - Onconova Therapeutics
      3.3. Early and later stage partnering - a risk/cost comparison
      3.4. What do companies spend on clinical stage partnering?
      3.5. Pure versus multi-component partnering deals
      3.6. Pure licensing agreement structure
      3.6.1. Example pure licensing agreements
      3.6.1.a. Case study : Argos Therapeutics - Medinet
      3.6.1.b. Case study : Pfizer - GlycoMimetics
      3.7. Multicomponent clinical stage partnering agreements
      3.7.1. Example multicomponent clinical stage clauses
      3.7.1.a. Case study: Gilead Sciences - GlobeImmune

      Chapter 4 - Clinical stage partnering payment strategies
      4.1. Introduction
      4.2. Clinical stage payment strategies
      4.3. Payment options
      4.3.1. Headline values
      4.3.2. Upfront payments
      4.3.2.1. Conditionality of upfront payments
      4.3.3. Loans
      4.3.4. Convertible loans
      4.3.5. Equity
      4.3.6. R&D funding
      4.3.7. Licensing fees
      4.3.8. Milestone payments
      4.3.9. Royalty payments
      4.3.9.1. Issues affecting royalty rates
      4.3.9.2. Royalties on combination products
      4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech
      4.3.9.3. Guaranteed minimum/maximum annual payments
      4.3.9.4. Royalty stacking
      4.3.9.5. Royalties and supply/purchase contracts
      4.3.10. Quids
      4.3.11. Option payments

      Chapter 5 - Trends in clinical stage deal making
      5.1. Introduction
      5.2. Clinical stage partnering over the years
      5.2.1. Trends in phase I deals since 2014
      5.2.1.1. Attributes of phase I deals
      5.2.2. Trends in phase II deals since 2014
      5.2.2.2. Attributes of phase II deals
      5.2.3. Trends in phase III deals since 2014
      5.2.3.1. Attributes of phase III deals
      5.3. Clinical stage partnering by deal type
      5.4. Clinical stage partnering by disease type
      5.5. Partnering by clinical stage technology type
      5.6. Clinical stage partnering by most active company since 2014

      Chapter 6 - Payment terms for clinical stage partnering
      6.1. Introduction
      6.2. Guidelines for clinical stage payment terms
      6.2.1. Upfront payments
      6.2.2. Milestone payments
      6.2.3. Royalty payments
      6.3. Clinical stage payment terms - deal data analysis
      6.3.1. Public data
      6.3.2. Survey data
      6.4. Payment terms analysis
      6.4.1. Clinical stage partnering headline values
      6.4.2. Clinical stage deal upfront payments
      6.4.3. Clinical stage deal milestone payments
      6.4.4. Clinical stage royalty rates
      6.5 Clinical stage median financials
      6.5.1. Clinical stage headline value
      6.5.2. Clinical stage upfront value
      6.5.3. Clinical stage milestone value
      6.5.4. Clinical stage royalty value

      Chapter 7 - Leading clinical stage deals
      7.1. Introduction
      7.2. Top clinical stage deals by value

      Chapter 8 - Top 25 most active clinical stage dealmakers
      8.1. Introduction
      8.2. Top 25 most active clinical stage dealmakers

      Chapter 9 - Clinical stage partnering contracts directory
      9.1. Introduction
      9.2. Clinical stage deals with contracts since 2014

      Chapter 10 - Clinical stage deal making by development stage
      10.1. Introduction
      10.2. Deals by clinical stage
      Phase I
      Phase II
      Phase III
      Regulatory
      Formulation

      Appendices

      Appendix 1 - Clinical stage dealmaking by companies A-Z
      Appendix 2 - Clinical stage dealmaking by industry sector
      Appendix 3 - Clinical stage dealmaking by stage of development
      Appendix 4 - Clinical stage dealmaking by therapy area
      Appendix 5 - Clinical stage dealmaking by technology type

      For more information about this report visit https://www.researchandmarkets.com/r/6zuz72

      Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

      Media Contact:

      Research and Markets
      Laura Wood, Senior Manager
      [email protected]

      For E.S.T Office Hours Call +1-917-300-0470
      For U.S./CAN Toll Free Call +1-800-526-8630
      For GMT Office Hours Call +353-1-416-8900

      U.S. Fax: 646-607-1907
      Fax (outside U.S.): +353-1-481-1716

      SOURCE Research and Markets

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.